Prof. Dr. PERVİN HÜRMÜZ

Yayın Ağı

Makaleler 72

1. The impact of malnutrition in the radiotherapy pathway in geriatric patients in the onco-surgical settings on behalf of the Turkish Society for Radiation Oncology Study Group (TROD 12-04)

YÜRÜT ÇALOĞLU V., Serarslan A., KANYILMAZ G., Saglam E. K., HÜRMÜZ P., ÇOLPAN ÖKSÜZ D., et al.

EJSO , sa.8, 2025 (SCI-Expanded, Scopus)

2. Comments on "Analysis of patients with locally advanced rectal cancer given neoadjuvant radiochemotherapy with or without RT dose intensification: A multicenter retrospective study ATLANTIS part I"

ÖZYÜREK Y., HÜRMÜZ P., YILDIZ F.

RADIOTHERAPY AND ONCOLOGY , 2025 (SCI-Expanded, Scopus)

3. Translation, Cross-Cultural Adaptation, and Psychometric Validation of the Turkish Version of the "Expanded Prostate Cancer Index Composite (EPIC)" in Prostate Cancer Patients

TİLKİ B., HÜRMÜZ P., YÜCE D., ÖZYİĞİT G., Akyol F.

PROSTATE , sa.7, ss.710-718, 2025 (SCI-Expanded, Scopus)

4. Evaluating the impact of cardiac substructure dosimetric parameters on survival in lung cancer patients undergoing postoperative radiotherapy

Yilmaz M. T., HÜRMÜZ P., GÜRLEK E., YILDIZ D., CENGİZ M.

STRAHLENTHERAPIE UND ONKOLOGIE , sa.4, ss.452-462, 2025 (SCI-Expanded, Scopus)

5. Prognostic Impact of Low Muscle Mass and Inflammatory Markers in Stage III Nonsmall Cell Lung Cancer Turkish Oncology Group and Turkish Society of Radiation Oncology Thoracic Cancer Study Group (08-005)

Gumustepe E., Yavas G., Kirakli E. K., DİNÇBAŞ H. F., Dilek N., HÜRMÜZ P., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , sa.2, ss.67-74, 2025 (SCI-Expanded, Scopus)

6. Multi-institutional analysis of extracranial oligometastatic colorectal cancer patients treated with stereotactic body radiation therapy: TROD 02-008 study

Guler O. C., HÜRMÜZ P., ATALAR B., Guney Y., Saglam E. K., AKYÜREK S., et al.

STRAHLENTHERAPIE UND ONKOLOGIE , cilt.200, ss.958-966, 2024 (SCI-Expanded, Scopus)

7. Patterns of Failure After Prostate-Only Radiotherapy in High-Risk Prostate Cancer: Implications for Refining Pelvic Nodal Contouring Guidelines in Regard to Singh et al.

Onaly C., Elmaliy A., HÜRMÜZ P.

CLINICAL ONCOLOGY , sa.9, 2024 (SCI-Expanded, Scopus)

8. Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy

Onal C., Guler O. C., ERPOLAT Ö. P., HÜRMÜZ P., Sutera P., Deek M. P., et al.

CLINICAL NUCLEAR MEDICINE , cilt.49, sa.8, 2024 (SCI-Expanded, Scopus)

9. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer

Sutera P., Deek M. P., Deek R. A., Guler O. C., HÜRMÜZ P., Reyhan M., et al.

ADVANCES IN RADIATION ONCOLOGY , cilt.9, sa.7, 2024 (ESCI, Scopus) Sürdürülebilir Kalkınma

10. Predicting Overall Survival for Patients Who Underwent Adjuvant Chemoradiotherapy for Gastric Cancer

Yilmaz M. T., HÜRMÜZ P., DAĞ O., YİĞİT E., Ozyure Y., AVCI H., et al.

RADIOTHERAPY AND ONCOLOGY , 2024 (SCI-Expanded, Scopus)

11. A Post-International Gastrointestinal Cancers Conference (IGICC) Position Statements '

YALÇIN Ş., Lacin S., Kaseb A. O., PEYNİRCİOĞLU B., Cantasdemir M., ÇİL B. E., et al.

JOURNAL OF HEPATOCELLULAR CARCINOMA , cilt.11, ss.953-974, 2024 (SCI-Expanded, Scopus)

12. The Impact of Dose Rate on the Tumor Microenvironment Using Flattening-filter-free Beams

YILMAZ M., Gok A., Gedik M., ÇAĞLAYAN A., YEDEKÇİ F. Y., AYDIN DİLSİZ S., et al.

Clinical Oncology , 2024 (SCI-Expanded, Scopus)

13. Radiation Oncologists' Approach to Rectosigmoid Junction Tumors in Turkey: The Turkish Society for Radiation Oncology Gastrointestinal Group Survey Study (TROD 02-007)

AYNACI Ö., Serdar L., CANYILMAZ E., HÜRMÜZ P.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.34, sa.9, ss.911-917, 2023 (SCI-Expanded, Scopus, TRDizin)

14. In Regard to Zeng et al.

Sari S. Y., KAHVECİOĞLU A., HÜRMÜZ P.

International Journal of Radiation Oncology Biology Physics , cilt.116, sa.3, ss.690, 2023 (SCI-Expanded, Scopus)

15. In regard to wandrey et al

Sari S., KAHVECİOĞLU A., HÜRMÜZ P.

Lung Cancer , cilt.179, 2023 (SCI-Expanded, Scopus)

16. Treatment outcomes of postoperative ultra-hypofractionated stereotactic body radiotherapy in prostate cancer

ÖZYİĞİT G., Onal C., BEDÜK ESEN Ç. S., TİLKİ B., HÜRMÜZ P.

Urologic Oncology: Seminars and Original Investigations , cilt.41, sa.5, 2023 (SCI-Expanded, Scopus)

17. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study

Onal C., Oymak E., Guler O. C., TİLKİ B., Yavas G., HÜRMÜZ P., et al.

Strahlentherapie und Onkologie , cilt.199, sa.5, ss.456-464, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

18. The Effect of Video-Based Education on Anxiety of Patients Receiving Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

BEDÜK ESEN Ç. S., YAZICI G., HÜRMÜZ P., ÖZYİĞİT G., Zorlu F.

JOURNAL OF CANCER EDUCATION , cilt.38, sa.2, ss.426-430, 2023 (SCI-Expanded, Scopus)

19. Planning and dosimetric evaluation of three total body irradiation techniques: Standard SSD VMAT, Extended SSD VMAT and Extended SSD Field-in-Field

Cananoglu M., HÜRMÜZ P., YEĞİNER M., ÖZYİĞİT G.

RADIATION AND ENVIRONMENTAL BIOPHYSICS , cilt.62, sa.1, ss.73-81, 2023 (SCI-Expanded, Scopus)

20. Treatment Outcomes of Stereotactic Body Radiotherapy in Patients with Synchronous and Metachronous Oligometastatic Renal Cell Carcinoma

Guler O. C., Oymak E., HÜRMÜZ P., Yavas G., TİLKİ B., Yavas C., et al.

Urologia Internationalis , cilt.107, sa.2, ss.171-178, 2023 (SCI-Expanded, Scopus)

21. Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study

Onal C., Guler O. C., HÜRMÜZ P., YAVAŞ G., TİLKİ B., Oymak E., et al.

STRAHLENTHERAPIE UND ONKOLOGIE , cilt.198, sa.10, ss.940-948, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

22. The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy

KAHVECİOĞLU A., Yilmaz M. T., HÜRMÜZ P.

The Lancet , cilt.400, sa.10356, ss.884-885, 2022 (SCI-Expanded, Scopus)

23. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma

Onal C., HÜRMÜZ P., Guler O. C., YAVAŞ G., TİLKİ B., Oymak E., et al.

CLINICAL & TRANSLATIONAL ONCOLOGY , cilt.24, sa.8, ss.1533-1541, 2022 (SCI-Expanded, Scopus)

24. SABR for Oligametastatic Disease

Kilicoglu G. S., HÜRMÜZ P.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , cilt.113, sa.3, ss.697, 2022 (SCI-Expanded, Scopus)

25. Comments on "Whole lung irradiation as a novel treatment for COVID-19: Final results of the prospective randomized trial (WINCOVID trial)"

ÖZYÜREK Y., Sari S., HÜRMÜZ P.

RADIOTHERAPY AND ONCOLOGY , cilt.170, ss.244-245, 2022 (SCI-Expanded, Scopus)

26. Definitive Chemoradiotherapy Results in Synchronous Oligometastatic Non-small Cell Lung Cancer Patients Turkish Society for Radiation Oncology Group Study (TROD 10-003)

DURU BİRGİ S., Akgun Z., HÜRMÜZ P., AKYÜREK S., Saglam E. K., YILMAZ M. T., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.45, sa.1, ss.40-47, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

27. National Multi-Center Observational Retrospective Study to Understand Treatment Patterns and Outcomes for Stage III Non-Small Cell Lung Cancer Patients in Turkey: Turkish Society for Radiation Oncology Study, STONE Trial

Onal C., DEMİRAL A. N., ATALAR B., YALMAN D., Dagoglu N., HÜRMÜZ P., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.32, sa.1, ss.23-34, 2022 (SCI-Expanded, Scopus, TRDizin)

28. Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease

Sezen D., Verma V., He K., Abana C. O., Barsoumian H., Ning M. S., et al.

SEMINARS IN RADIATION ONCOLOGY , cilt.31, sa.3, ss.217-226, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

29. Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?

HÜRMÜZ P., ÖZYİĞİT G., Kilickap S., BEDÜK ESEN Ç. S., AKDOĞAN B., Ozen H., et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

30. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using Ga-68-PSMA PET/CT TROD 09-004 Study

Onal C., ÖZYİĞİT G., Akgun Z., Atalar B., Igdem S., Oymak E., et al.

CLINICAL NUCLEAR MEDICINE , cilt.46, sa.6, ss.465-470, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

31. Factors affecting post-treatment radiation-induced lung disease in patients receiving stereotactic body radiotherapy to lung

HÜRMÜZ P., CENGİZ M., Esen C. S. B., Yedekci Y., YILDIZ Z., ÖZYİĞİT G., et al.

Radiation and Environmental Biophysics , cilt.60, ss.87-92, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

32. Neoadjuvant Radiotherapy in Rectal Cancer: A Single Center Experience

HÜRMÜZ P., TİLKİ B., CENGİZ M., YILDIZ F., ÖZYİĞİT G., EROL T., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.31, sa.3, ss.178-184, 2021 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

33. Does Intravesical Prostatic Protrusion Affect Oncological Outcomes and Toxicity in Prostate Cancer Patients Receiving Definitive Radiotherapy?

HÜRMÜZ P., BEDÜK ESEN Ç. S., Unal E., KARÇAALTINCABA M., ÖZYİĞİT G., AKYOL H. F.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.31, sa.1, ss.1-7, 2021 (SCI-Expanded, Scopus, TRDizin)

34. Hyaluronic acid spacer in focal prostate reirradiation: A single centre experience

ÖZYİĞİT G., HÜRMÜZ P., AKINCI D., Esen S. C. B., YILMAZ M., AKDOĞAN B., et al.

CANCER RADIOTHERAPIE , cilt.24, sa.8, ss.805-811, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

35. Treatment outcomes of metastasis-directed treatment using(68)Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002)

HÜRMÜZ P., Onal C., ÖZYİĞİT G., Igdem S., Atalar B., Sayan H., et al.

STRAHLENTHERAPIE UND ONKOLOGIE , cilt.196, sa.11, ss.1034-1043, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

36. Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients

Onal C., Ozyigit G., Cem G., Hurmuz P., Torun N., Tuncel M., et al.

RADIOTHERAPY AND ONCOLOGY , cilt.151, ss.222-227, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

37. Stereotactic body radiotherapy in patients with early-stage non-small cell lung cancer: Does beam-on time matter?

HÜRMÜZ P., CENGİZ M., ÖZYİĞİT G., Akkas E. A., YÜCE D., YILMAZ M. T., et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , cilt.50, sa.10, ss.1182-1187, 2020 (SCI-Expanded, Scopus)

38. Comments on "Risk factors for vertebral compression fracture after spine stereotactic body radiation therapy: Long-term results of a prospective phase 2 study"

YILMAZ M. T., HÜRMÜZ P.

RADIOTHERAPY AND ONCOLOGY , cilt.145, ss.127, 2020 (SCI-Expanded, Scopus)

39. FLASH-radiotherapy: A new perspective in immunotherapy era?

YILMAZ M. T., HÜRMÜZ P., YAZICI G.

RADIOTHERAPY AND ONCOLOGY , cilt.145, ss.137, 2020 (SCI-Expanded, Scopus)

40. Hypofractionated radiotherapy for non-metastatic bone and soft tissue sarcomas

SARI S., CENGİZ M., Dauletkazin A., YAZICI G., GÜLTEKİN M., HÜRMÜZ P., et al.

CANCER RADIOTHERAPIE , cilt.23, sa.8, ss.853-859, 2019 (SCI-Expanded, Scopus)

41. Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapy

ÖZYİĞİT G., Onal C., Igdem S., Alicikus Z. A., Iribas A., Akin M., et al.

STRAHLENTHERAPIE UND ONKOLOGIE , cilt.195, sa.10, ss.882-893, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

42. Integration of 68Ga-PSMA-PET/CT in Radiotherapy Planning for Prostate Cancer Patients

Onal C., Torun N., Akyol F., Guler O. C., HÜRMÜZ P., Yildirim B. A., et al.

CLINICAL NUCLEAR MEDICINE , cilt.44, sa.9, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

43. Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer

ÖZYİĞİT G., HÜRMÜZ P., YÜCE D., Akyol F.

WORLD JOURNAL OF CLINICAL ONCOLOGY , cilt.10, sa.8, ss.283-292, 2019 (ESCI) Sürdürülebilir Kalkınma

44. Long Term Follow-Up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer In Regard to Videtic et al

YILMAZ M. T., HÜRMÜZ P., CENGİZ M.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , cilt.104, sa.2, ss.466-467, 2019 (SCI-Expanded, Scopus)

45. Sub-Castrate Testosterone Nadir and Clinical Outcomes in Intermediate or High-Risk Localized Prostate Cancer

HÜRMÜZ P., ÖZYİĞİT G.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , cilt.104, sa.1, ss.224-225, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

46. Concurrent Immune Checkpoint Inhibitors and Radiation Therapy

YILMAZ M. T., HÜRMÜZ P., CENGİZ M.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , cilt.101, sa.4, ss.998, 2018 (SCI-Expanded, Scopus)

47. A Phase II Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-risk Medically Inoperable Early-stage Non-small Cell Lung Cancer

HÜRMÜZ P., ÖZYİĞİT G.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , cilt.101, sa.3, ss.744-745, 2018 (SCI-Expanded, Scopus)

48. Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer

HÜRMÜZ P., CENGİZ M., Zorlu F., Akyol F.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , cilt.100, sa.4, ss.1079-1080, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

49. Küçük Hücreli Dışı Akciğer Kanserlerinde Definitif Kemoradyoterapi

YÜCE SARI S., HÜRMÜZ P., AKYOL H. F.

Türkiye Klinikleri Radyasyon Onkolojisi Özel Dergisi , cilt.4, sa.1, ss.52-59, 2018 (TRDizin) Sürdürülebilir Kalkınma

50. Investigating the surface dose contribution of intrafractional kV imaging in CyberKnife-based stereotactic radiosurgery

Canbolat A., Zorlu F., HÜRMÜZ P., YEĞİNER M., ÖZYİĞİT G.

MEDICAL DOSIMETRY , cilt.42, sa.4, ss.304-309, 2017 (SCI-Expanded, Scopus)

51. Prevalence of Complementary Medicine Use in Patients With Cancer: A Turkish Comprehensive Cancer Center Experience

YALÇIN Ş., HÜRMÜZ P., McQuinn L., Naing A.

JOURNAL OF GLOBAL ONCOLOGY , cilt.4, 2017 (ESCI, Scopus) Sürdürülebilir Kalkınma

52. Reirradiation of Pediatric Tumors Using Hypofractionated Stereotactic Radiotherapy.

GULTEKIN M., CENGIZ M., SEZEN D., ZORLU F., YILDIZ F., Yazici G., et al.

Technology in cancer research & treatment , cilt.16, ss.195-202, 2017 (SCI-Expanded, Scopus)

53. The dosimetric impact of implants on the spinal cord dose during stereotactic body radiotherapy

YAZICI G., SARI S., YEDEKÇİ F. Y., Yucekul A., BIRGI S. D., DEMIRKIRAN G., et al.

RADIATION ONCOLOGY , cilt.11, 2016 (SCI-Expanded, Scopus)

54. Robotic Stereotactic Body Radiation Therapy in Patients With Recurrent or Metastatic Abdominopelvic Tumors: A Single Institute Experience

Sezen D., GÜRKAYNAK H. M., GÜLTEKİN M., CENGİZ M., YILDIZ F., ZORLU A. F., et al.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT , cilt.15, sa.1, ss.203-211, 2016 (SCI-Expanded, Scopus)

55. Evaluation of the Effect of Changes in Dose Rate on Rat Lung Cells

HÜRMÜZ P., KIVANC H., CANBOLAT A., Yavas G., YÜCE D., ÖNDER S. Ç., et al.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT , cilt.14, sa.3, ss.343-349, 2015 (SCI-Expanded, Scopus)

56. Three Dimensional Conformal Radiotherapy and Androgen Deprivation Therapy in Patients with Clinically Localized Prostate Cancer; Hacettepe University Experience

ÖZDEMİR Y., Akyol F., ÖZYİĞİT G., HÜRMÜZ P., Onal C., Selek U., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.25, sa.2, ss.107-117, 2015 (SCI-Expanded, Scopus, TRDizin)

57. Assessment of uterus position as a surrogate for high-risk clinical target volume with respect to the applicator position for multiple fractions of brachytherapy in cervical cancer

Cooper R., Brearley E., HÜRMÜZ P., Musunuru H. B., Richardson C., Swift S., et al.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS , cilt.290, sa.6, ss.1201-1205, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

58. Impact of locoregional treatment on survival in patients presented with metastatic breast carcinoma

GÜLTEKİN M., Yazici O., Eren G., YÜCE D., AKSOY S., Ozisik Y., et al.

BREAST , cilt.23, sa.6, ss.775-783, 2014 (SCI-Expanded, Scopus)

59. Robotic Stereotactic Radiosurgery in Patients with Nasal Cavity and Paranasal Sinus Tumors

ÖZYİĞİT G., CENGİZ M., HÜRMÜZ P., YAZICI G., GÜLTEKİN M., Akyol F., et al.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT , cilt.13, sa.5, ss.409-413, 2014 (SCI-Expanded, Scopus)

60. Metaplastic Breast Carcinoma: a Heterogeneous Disease

GÜLTEKİN M., Eren G., Babacan T., YILDIZ F., Altundag K., GÜLER N., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.6, ss.2851-2856, 2014 (SCI-Expanded, Scopus)

61. RADIOTHERAPY IN THE TREATMENT OF ELDERLY GLIOBLASTOMA PATIENTS

HÜRMÜZ P., ÖZYİĞİT G., CENGİZ M., YÜCE D., GÜLTEKİN M., YAZICI G., et al.

TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI , cilt.17, sa.2, ss.134-137, 2014 (SCI-Expanded, SSCI, Scopus, TRDizin)

62. A simple strategy to decrease fatal carotid blowout syndrome after stereotactic body reirradiaton for recurrent head and neck cancers

YAZICI G., Sanli T. Y., CENGİZ M., YÜCE D., GÜLTEKİN M., HÜRMÜZ P., et al.

RADIATION ONCOLOGY , cilt.8, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

63. Robotic Stereotactic Radiosurgery in Patients with Unresectable Glomus Jugulare Tumors

HÜRMÜZ P., CENGİZ M., ÖZYİĞİT G., YAZICI G., AKYOL F., YILDIZ F., et al.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT , cilt.12, sa.2, ss.109-113, 2013 (SCI-Expanded, Scopus)

64. Determination of gonad doses during robotic stereotactic radiosurgery for various tumor sites

Zorlu F., Dugel G., ÖZYİĞİT G., HÜRMÜZ P., CENGİZ M., YILDIZ F., et al.

MEDICAL PHYSICS , cilt.40, sa.4, 2013 (SCI-Expanded, Scopus)

65. Determination of the Planning Target Volume Margin by the Use of kv Portal Imaging and kvCone Beam Computerized Tomography

YAZICI G., YEĞİNER M., Atamel M., HÜRMÜZ P., GÜLTEKİN M., CENGİZ M., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.23, sa.4, ss.254-259, 2013 (SCI-Expanded, Scopus, TRDizin)

66. Utility of "Over D1" or D1 Nodal Dissections in Predicting Outcome of Patients with Gastric Adenocarcinoma Treated with Postoperative Concurrent Chemoradiotherapy

SELEK U., Zorlu F., ÖZYİĞİT G., HÜRMÜZ P., YALÇIN Ş., CENGİZ M.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.4, ss.233-238, 2012 (SCI-Expanded, Scopus, TRDizin)

67. PEMETREXED-CARBOPLATIN DOUBLETS SHOWED BETTER MEDIAN SURVIVAL THAN PEMETREXED-CISPLATIN IN THE TREATMENT OF TURKISH MALIGNANT PLEURAL MESOTHELIOMA PATIENTS

Emri S., HÜRMÜZ P., KADILAR C., CANGIR A., Zorlu F., DOĞAN R., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.6, sa.6, 2011 (SCI-Expanded, Scopus)

68. Symmetrical primary cutaneous marginal zone lymphoma associated with rheumatoid arthritis

YILDIRIM F., KARADUMAN A., HÜRMÜZ P., Ozyar E., BARIŞTA İ., Saglam A.

JOURNAL OF CUTANEOUS PATHOLOGY , cilt.37, sa.5, ss.600-604, 2010 (SCI-Expanded, Scopus)

69. The Efficiency and Toxicity of Hemithoracic Radiotherapy After Extra Pleural Pneumonectomy in Malign Pleural Mesothelioma

HÜRMÜZ P., Akyol F., SELEK U., ÖZYİĞİT G., DOĞAN R., Ozdemir N., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.20, sa.1, ss.20-26, 2010 (SCI-Expanded, Scopus, TRDizin)

70. Lung adenocarcinoma with skin metastasis

HÜRMÜZ P., SELEK U., Zorlu F., Tekuzman G.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.18, sa.1, ss.39-41, 2008 (SCI-Expanded, Scopus, TRDizin)

71. Craniospinal radiotherapy in adult medulloblastoma

Selek U., Zorlu F., Hurmuz P., Cengiz M., Turker A., Soylemezoglu F., et al.

STRAHLENTHERAPIE UND ONKOLOGIE , cilt.183, sa.5, ss.236-240, 2007 (SCI-Expanded, Scopus)

72. Mold brachytherapy in Bowen's disease: a case report and review of the literature

HÜRMÜZ P., ERSOY EVANS S., Yapici B., Gurdalli S., Saglam Y., ŞAHİN S., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.21, sa.2, ss.102-106, 2006 (ESCI, TRDizin)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 16

1. Treatment outcomes of metastasis-directed treatment using 68 Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002)

HÜRMÜZ P., ÖNAL H. C., ÖZYİĞİT G., İĞDEM M. Ş., ATALAR B., sayan h., et al.

Türk Radyasyon Onkolojisi sanal Kongresi, Türkiye, 20 - 22 Kasım 2020, (Özet Bildiri) Sürdürülebilir Kalkınma

2. Gleason skoru 10 prostat kanserierinde definif radyoterapi ve ADT sonuçları: TROD09-001 ÜRO- ONKOLOJİ GRUBU ÇALıŞMASI

HÜRMÜZ P., ÖNAL H. C., İribaş A., ALSAN ÇETİN İ., Akbulut S., GÖRKEN İ., et al.

Türk radyasyon onkolojisi derneği sanal kongre, Türkiye, 20 - 22 Kasım 2020, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

3. Evaluation of Prognostic Biomarkers in Stage III Non-Small Cell Lung Cancer Turkish Radiation Oncology Group Lung Cancer Studying Group

GÜMÜŞTEPE E., YAVAŞ G., korkaz kıraklı e., YILMAZ M. T., ÖZLER T., HÜRMÜZ P., et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 25 - 28 Ekim 2020, cilt.108, ss.104-105, (Özet Bildiri) Sürdürülebilir Kalkınma

4. Interpreting Clinical Parameters and Nomograms for Predicting Lymph Node Metastasis Detected with 68 Ga-PSMAPET/CT in prostate cancer patients

ÖNAL H. C., ÖZYİĞİT G., Oymak E., GÜLER O. C., HÜRMÜZ P., TİLKİ B., et al.

62nd Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), 25 Ekim - 28 Aralık 2020, (Özet Bildiri) Sürdürülebilir Kalkınma

5. Evaluation of Prognostic Biomarkers in Stage III Non-Small Cell Lung Cancer Turkish Radiation Oncology Group Lung Cancer Studying Group

GÜMÜŞTEPE E., YAVAŞ G., Kirakli E. K., YILMAZ M. T., Özler T., HÜRMÜZ P., et al.

62nd Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), 25 Ekim 2020, (Özet Bildiri) Sürdürülebilir Kalkınma

6. Definitive Chemoradiotherapy in Esophageal Squamous Cell Cancer: A Single Center Experience

YILMAZ M. T., HÜRMÜZ P., CENGİZ M., YÜCE D., ZORLU A. F., AKYOL H. F., et al.

9th International Gastrointestinal Cancer Conference, İstanbul, Türkiye, 6 - 08 Aralık 2019 Sürdürülebilir Kalkınma

7. the role of neoadjuvant radiotherapy in rectal cancer: hacettepe university experience

HÜRMÜZ P., TİLKİ B., YILDIZ F., ÖZYİĞİT G., EROL T., KONAN A., et al.

9th international gastrointestinal cancer conference, 6 - 08 Aralık 2019, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

8. DEFİNİTİVE CHEMORADİOTHERAPY İN ESOPHAGEAL S@UAMOUS CELL CANCER A SİNGLE CENTER EXPERİENCE

HÜRMÜZ P., CENGİZ M., YÜCE D., ZORLU A. F., AKYOL H. F., YALÇIN Ş., et al.

9 th international gastrointestinal cancer conference, 6 - 08 Aralık 2019, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

9. non-operative management of rectal cancer: hacettepe university experience

TİLKİ B., HÜRMÜZ P., CENGİZ M., ZORLU A. F., ÖZYİĞİT G., YILDIZ F., et al.

9th international gastrointestinal cancer conference, 6 - 08 Aralık 2019, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

10. National, Observational, Multicentric Study in Stage III Non-Small Cell Lung Cancer Patients in Turkey: Stone Trial

ÖNAL H. C., ATALAR B., DEMİRAL A. N., YALMAN D., Gül Ş., HÜRMÜZ P., et al.

IASLC WCLC 2019, 7 - 10 Eylül 2019, cilt.14, ss.1067, (Özet Bildiri)

11. The Role of (68)ga-PSMA-PET/CT in Pelvic FIELD Delineation in Prostate Cancer Patients with Pelvic Lymph Node Metastasis

Onal C., HÜRMÜZ P., Torun N., TUNCEL M., Guler O. C., Reyhan M., et al.

61st Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), Illinois, Amerika Birleşik Devletleri, 15 - 18 Eylül 2019, cilt.105, (Özet Bildiri)